


# Research Transparency Panel Meeting Summary

**Novartis**

3rd December 2024

15:00–16:30



# Data Access Proposal Request

## Flatiron Health UK RWD Products

- Prostate Cancer

## Attendees

### FLATIRON HEALTH UK

- Adam Manhi (chair)
- Emma Salib (programme manager)

### RESEARCH TRANSPARENCY PANEL

- Jennifer McCaffery (lay)
- Hayley Hall (lay)
- Sonia Patton (patient)
  - Trishna Bharadia (patient)
- Yanrong Jiang (clinical)

## Conflicts of interest

No conflicts declared by panel

## Decision outcome

Approved

## Summary of discussion

- Broad agreement the lay summary was clear, well-written and easy to follow.
- Clear cohort with unmet need and limited treatment options which become less effective over time.
- Comprehensive explanation of use cases, including analyses and patient benefit.
- Clear case for why access to RWD is required, giving more representative insights than clinical trials.
- Transparent explanation of previous work with Flatiron and positive impact.
- The panel raised several comments on other aspects of the application including:
  - Patient cohort with 'unmet need' could have been elaborated on further (e.g. # patients; survival rates; side effects of current medications).

- Further detail on Novartis plans for indications in metastatic prostate cancer would be appreciated.
- More detail could have been provided on DEI (e.g. existing health inequalities; examples of Novartis' DEI work).
- Would have liked more information on how Novartis would engage with patients through the process, including integrating feedback and disseminating findings.